Godavari Biorefineries' Sathgen Therapeutics Division Expands to U.S. with Princeton Based Subsidiary

Godavari Biorefineries Ltd, a leading renewable chemicals and bio-based manufacturing conglomerate, has announced the incorporation of Sathgen Therapeutics LLC, a wholly owned step-down subsidiary based in Princeton, New Jersey, USA. This strategic expansion strengthens GBL’s clinical-stage biotechnology presence in the United States, with a primary focus on global out-licensing of intellectual property and to build the network to accelerate the drug-development programme. Sathgen Therapeutics has secured patents in US, Europe, China, and other key markets for several candidates that have shown promising preclinical efficacy, particularly in triple-negative breast cancer (TNBC) and novel class of compounds that inhibit cancer and cancer stem cells in vitro, with strong activity observed in breast and prostate cancer models. Sathgen has formed a Scientific Advisory Board (SAB) to guide its clinical-development and translational-research strategy. The SAB includes Dr. Razelle Kurzrock and Dr. Massimo Cristofanilli, internationally known authorities in precision oncology, immunotherapy, and early-phase clinical trials, and metastatic breast cancer and cancer biology, respectively.